{
    "2019-10-11": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Why Johnson & Johnson Stock Can Weather Legal Awards Against It",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Stock",
                        "Legal Awards"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "What to Expect from Q3 Earnings Season with Big Banks Set to Report?",
                "features": {
                    "keywords": [
                        "Q3 Earnings",
                        "Big Banks"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "J&J CEO touts Philadelphia's potential to be the 'Silicon Valley of health care'",
                "features": {
                    "keywords": [
                        "J&J",
                        "CEO",
                        "Philadelphia",
                        "Silicon Valley",
                        "health care"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Johnson & Johnson Stock Has Limited Upside",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Stock",
                        "Limited Upside"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals",
                "features": {
                    "keywords": [
                        "Pharma Stock",
                        "NVS",
                        "FDA Nod",
                        "NVO",
                        "GSK",
                        "PFE"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Will Q3 Earnings Drive Dow ETF Higher?",
                "features": {
                    "keywords": [
                        "Q3 Earnings",
                        "Dow ETF"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "J&J Rises After Analyst Calls Pharma Giant's Shares a Bargain",
                "features": {
                    "keywords": [
                        "J&J",
                        "Analyst",
                        "Shares",
                        "Bargain"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Geron Starts Enrollment in Phase III MDS Study on Imetelstat",
                "features": {
                    "keywords": [
                        "Geron",
                        "Phase III",
                        "MDS Study",
                        "Imetelstat"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",
                "features": {
                    "keywords": [
                        "Therapix",
                        "Merger Deadline",
                        "Five Prime",
                        "Restructures",
                        "Gilead-Galapagos",
                        "Rheumatism Drug"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}